Medical Oddities: Prayer for Pain? - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Medical Oddities: Prayer for Pain?

This week’s research collection showed that biology, behavior, and environment often intersect in unexpected ways.

  • By

  • Teraya Smith

  • June 3, 2026

  • 6 min

Share

Clinical Scorecard: Prayer for Pain?

At a Glance

CategoryDetail
Condition
Key MechanismsIn-person Christian proximal intercessory prayer vs. relaxing music (source needed)
Target Population
Care Setting

Key Highlights

  • 162 participants with pain reported 1- to 2-point greater reductions in pain after prayer intervention (source needed).
  • 111 participants with anxiety showed improvements on GAD-7 assessments through 6 weeks (source needed).
  • Study population was predominantly Black (83%), female (78%), and low-income (source needed).
  • No adverse events reported; 97% of participants were neutral or agreed to future prayer opportunities (source needed).

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider offering prayer as a complementary intervention for pain and anxiety (source needed).

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Prayer may provide a unique intervention (source needed).

        Clinical Best Practices

          Related Resources & Content

          Original Source(s)

          Medical Oddities: Prayer for Pain?

          • by Teraya Smith

          • June 3, 2026

          Related Content

          Side Effects: Bro Science, Actually

          Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.

          FDA Grants Traditional Approval to Iptacopan in Primary IgAN

          Novartis reported less annual eGFR decline with iptacopan than placebo over 2 years in the phase 3 APPLAUSE-IgAN trial.

          Barriers and facilitators impacting access to sexual and reproductive health services for women with intellectual disability